FMFarhad Al Marzook

Farhad Al Marzook

*This is an algorithmically generated author record based on publicly available information.

Farhad Al Marzook has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preoperative Use of GLP-1 Receptor Agonists Is Associated With Reduced Risk of Postoperative DVT and Mortality in Patients Undergoing Lumbar Laminectomy

    by Farhad Al Marzook, Ahad A. Kesaria, James M. Glover, Pouya Alijanipour

    Study Design: Retrospective cohort study. Objective: To evaluate the association between preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and postoperative outcomes in patients undergoing lumbar laminectomy. Summary of Background Data: GLP-1 RAs have gained prominence for their weight management benefits. Emerging evidence suggests their preoperative use may reduce postoperative complications, but data specific to lumbar laminectomy are limited. Methods: We conducted a retrospective cohort study using the TriNetX research database to identify patients undergoing lumbar laminectomy over the past 20 years using Current Procedural Terminology (CPT) codes 63047 and 63048. Patients were stratified into 2 cohorts, those who used GLP-1 RAs within 1 year preoperatively and those who did not. Propensity score matching (PSM) was performed at a 1:1 ratio to balance demographics and medical comorbidities, including race, age at index surgery, gender, ethnicity, hypertension, diabetes, obesity, and other comorbidities. The primary outcomes were 180-day medical complications postoperatively. Using χ 2 analysis, risk ratios (RRs), 95% CI, and P values were calculated, with statistical significance at P P =0.0034) and a 43% reduction in all-cause mortality (0.8% vs. 1.4%, RR=0.551, 95% CI: 0.359–0.847, P =0.0058) compared with nonusers. Conclusions: Preoperative GLP-1 RA use is associated with a reduced postoperative risk of DVT and mortality in patients undergoing lumbar laminectomy. These findings suggest GLP-1 RAs may have a protective association in the postoperative period. Future prospective studies are warranted to validate these results and explore underlying mechanisms. Level of Evidence: Level III—retrospective, comparative cohort study.


  • Intercuneiform Instability Following Triplanar Tarsometatarsal Arthrodesis

    by Farhad A. Marzook, Reyhan Meetheen, Ashton R. Davis, Jie Chen

    Case: A 78-year-old man with osteoarthritis and progressive hallux valgus underwent triplanar first tarsometatarsal (TMT) arthrodesis using the Lapiplasty system. Despite successful fusion, postoperative radiographs demonstrated progressive intercuneiform diastasis with recurrence of deformity and midfoot discomfort. Conclusion: Intercuneiform instability may progress despite successful first TMT fusion and adjunct intercuneiform stabilization. In cases of ligamentous insufficiency, fixation alone may be inadequate, and supplemental intercuneiform fixation or arthrodesis should be considered.

  • Prescription Analysis of Antihistamines’ Use in Patients With Moderate to Severe Burns

    by Abbas A Karim, Nizam Karim, Suhaib Shah, Rashid Syed, Zain Akbar, Farhad Marzook, Juquan Song, George Golovko, Steven E Wolf, Amina El Ayadi

    Postburn pruritus (PBP) significantly affects patients, causing discomfort and hindering recovery. Antihistamines, which block H1 receptors, are commonly prescribed for PBP, yet large-scale studies on their usage patterns are limited. This study evaluates antihistamine prescription trends and provider practices for PBP across varying burn severities from moderate to severe burns (≥20% TBSA). A treatment-pathways analysis was performed using TriNetX, a global, federated, deidentified database. Patients with burns ≥ 20% TBSA from the past 20 years (2004-2024) who developed pruritus were identified and stratified into 4 cohorts: 20%-40%, 40%-60%, 60%-80%, and ≥ 80% TBSA. The analysis evaluated trends in antihistamine prescriptions, including the number of patients treated with antihistamines, types prescribed, and median times to treatment initiation, duration, and therapy switching. The total sample included 2754 patients (20%-40% TBSA, n = 1712; 40%-60%, n = 613; 60%-80%, n = 253; ≥80%, n = 176). Over 70% received antihistamines, with hydroxyzine as the most common first-line therapy, followed by diphenhydramine. Across all cohorts, the average of the median times for initiation, therapy duration, and time before switching was 16.75 days, 90.25 days, and 27.75 days, respectively. Significant variations in the timing of therapy initiation suggest a gap in consistent symptom management during critical recovery periods, potentially affecting patient comfort and overall outcomes. These findings underscore the importance of vigilant postburn assessment, stepwise escalation based on response, and complementary strategies to optimize PBP management. Frequent switching and prolonged durations suggest a need for more effective and tailored therapeutic approaches to improve recovery outcomes for patients with burn injuries.

  • Open Access

    Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery

    by Ahad A. Kesaria, Farhad A. Marzook, James M. Glover, Pouya Alijanipour

    Study Design: Retrospective Cohort Study. Objectives: This study evaluates the association between preoperative GLP-1 RA (glucagon-like-peptide-1 receptor antagonist) use and postoperative outcomes in patients undergoing lumbar fusion surgery. Methods: TriNetX database identified patients undergoing lumbar fusion within 20 years using Current Procedural Terminology (CPT). Patients were categorized by GLP-1 RA use within 1 year preoperatively. 1:1 propensity score match (PSM) balanced demographics and comorbidities including race/ethnicity, age, gender, hypertension, diabetes, obesity, nicotine dependence, sleep apnea, ischemic heart diseases, chronic kidney disease, acute kidney failure, mood disorders, asthma, chronic obstructive pulmonary disease, heart failure, alcohol dependence, anemia, and vitamin D deficiency. Primary outcomes were 1-year complications postoperatively. Chi-square analysis, risk ratios (RRs), 95% confidence intervals (CI), and P -values were calculated; significance was P < 0.05. Results: 4331 patients using preoperative GLP-1 RA were propensity score-matched with 179,268 controls without GLP-1 RA use, resulting in 4331 patients in each cohort after matching. At 1 year, GLP-1 RA users had significant reductions in DVT (1.4% vs 2.3%, RR = 0.64, 95% CI [0.464-0.883], P = 0.0061), PE (1.1% vs 1.6%, RR = 0.689, 95% CI [0.476-0.997], P = 0.0466), sepsis (4.0% vs 5.0%, RR = 0.811, 95% CI [0.66-0.995], P = 0.0447), all-cause mortality (2.1% vs 4.6%, RR = 0.46, 95% CI [0.36-0.589], P < 0.0001), pneumonia (2.4% vs 3.3%, RR = 0.716, 95% CI [0.548-0.936], P = 0.0139), and pseudoarthrosis (8.9% vs 13.8%, RR = 0.642, 95% CI [0.564-0.732], P < 0.0001) compared to non-users. Conclusions: Preoperative GLP-1 RA use is associated with a reduction in postoperative complications following lumbar fusion surgery. Further research is necessary to elucidate the underlying mechanisms and evaluate long-term outcomes.